What will Ginkgo Bioworks foundry revenue be in the first quarter of 2023?
Scaling production of synthetic biology processes remains a key challenge (Institution of Engineering and Technology, Harvard Business Review). Gingko Bioworks foundry and codebase offers a platform to facilitate scaling both the research and production processes of their customers by programming and manufacturing cells on their behalf (Gingko Bioworks, Forbes, Nasdaq). These “cell programs” allow companies to manufacture food, pharmaceutical, and petrochemical products through biological processes (Gingko Bioworks).
This question will be resolved based on Ginkgo Bioworks’ first quarter financial report, which can be found on their investment web page. Foundry revenue for Q2 2022 can be found on slide 12 of the Q2 presentation and page 7 of the SEC filing.
Additional Resources:
Additional Resources:
Outcome
| Answer | Final crowd forecast | Resolution |
|---|---|---|
| Less than $30 million | 4% | Did not happen |
| More than or equal to $30 million but less than $45 million | 16% | Happened |
| More than or equal to $45 million but less than $60 million | 55% | Did not happen |
| More than or equal to $60 million but less than $75 million | 22% | Did not happen |
| More than or equal to $75 million | 2% | Did not happen |
“Final crowd forecast” is the last aggregate crowd probability computed before the question closed – the right-hand end of the chart below, which this table is the accessible equivalent of.
Crowd forecast over time
More than or equal to $45 million but less than $60 million
More than or equal to $60 million but less than $75 million
More than or equal to $75 million
More than or equal to $30 million but less than $45 million
Less than $30 million